跳至主要内容
临床试验/ACTRN12622000723785
ACTRN12622000723785尚未招募2 期

Phase IIa randomized, placebo-controlled, double-blind crossover pilot study of tolerability and efficacy of cannabidiol (CBD) and palmitoylethanolamide (PEA) applied to the skin for the relief of osteoarthritic joint pain.

Westmead Hospital0 个研究点目标入组 72 人开始时间: 2022年5月20日最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
72

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
30 Years 至 90 Years(—)
性别
All

入选标准

  • 1. Diagnosis of OA defined by X-ray evidence of joint damage;
  • 2. Age 30–90;
  • 3. Disease duration of 2 years or more;
  • 4. Continued pain in any of the knee, hip, hands or lower lumbar spine joints despite oral
  • medications;
  • 5. No previous use of oral or smoked cannabinoids for pain management; able to complete
  • questionnaire;
  • 6. Able to attend outpatient clinic at monitoring and follow-up time points.

排除标准

  • 1. History of psychiatric disorder;
  • 2. History of drug dependency;
  • 3. Known sensitivity to cannabinoid agents;
  • 4. History of epilepsy; patient pain explained by fibromyalgia;
  • 5. Recurrent or recent malignancy;
  • 6. Pregnancy or breastfeeding;
  • 7. Change of pain medication in the preceding 4 weeks;
  • 8. Severe renal or liver dysfunction (patient excluded if there is an elevation of baseline liver enzymes);
  • 9. Concomitant medications: Prior or current cannabis use; current use of valproate, clobazam, topiramate, and/or rufinamide.

研究者

发起方
Westmead Hospital

相似试验